Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00946530|
Recruitment Status : Completed
First Posted : July 27, 2009
Results First Posted : March 29, 2017
Last Update Posted : October 3, 2018
|Condition or disease||Intervention/treatment||Phase|
|Sleep Initiation and Maintenance Disorders||Device: Bright light Device: Control||Not Applicable|
- Efficacy: Up to 4 weeks of morning bright light exposure will be more efficacious than morning dim light in consolidating nighttime sleep as assessed by actigraphy.
- Predictors of response: We expect the primary predictor of treatment response will be initial MMSE score. Secondary predictors include baseline sleep/wake and circadian parameters and age.
- Effectiveness: Bright light treatment will be more effective than dim light in improving quality of life.
- An understanding of some of the genetic markers of memory and/or sleep problems.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||118 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease|
|Study Start Date :||September 2004|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
Experimental: Bright Light
received bright light
Device: Bright light
Participants uses bright light
Placebo Comparator: Control
received regular light
Participants uses dim light
- Total Sleep Time [ Time Frame: 2 weeks ]The amount of actual sleep time in a sleep episode.
- WASO (Wake After Sleep Onset) [ Time Frame: 2 weeks ]WASO (Wake After Sleep Onset): the amount of time test subjects have spent awake after initially falling sleep and before they awaken for good.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00946530
|United States, California|
|VA Palo Alto Health Care System|
|Palo Alto, California, United States, 94304|
|Principal Investigator:||Jerome A Yesavage||Stanford University|